October 17, 2019
On September 23, 2019, Sandoz Inc. issued a voluntary recall of Ranitidine Hydrochloride Capsules 150mg and 300mg due to an elevated amount of unexpected impurity, N-Nitrosodimethylamine (NDMA) in the product.
Patients are asked to continue taking their medication and speak to their provider about alternate healthcare treatment options. Pharmacies will be asked to immediately stop dispensing Sandoz Ranitidine Hydrochloride Capsules.
Visit the FDA website for more information on the recalled products including product names, catalog numbers, lot numbers, and expiration dates. For other questions, email provider.relationswest@premera.com.